Radar · Life Sciences in Bavaria
Best Life Sciences Companies in Bavaria, Germany
The 291 best Life Sciences companies in Bavaria, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MorphoSys.
By Rohit KhannaTrends & Stories
291companies tracked
$4.1Bdisclosed funding
1unicorns
119have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × BAVARIA
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
50companies analysed
51%cloud-native stacks
2024funding peak (by rounds)
2016median founding year
40median Fliar Index™
333kcombined LinkedIn audience
61%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Bavaria
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MorphoSys Developer of antibodies for treating cancer | $770M | 68 mo ago | Acquired | 732 | Andreas Pluckthun Co-Founder | — | 1,338 patents Therapeutic antibody engineering, formulation, and purification processes for targeted immunotherapies | — |
| 2 | ITM Developer of radiopharmaceuticals and radioisotopes for cancer treatment 27Funding top 25%Growth top 35%Moat top 42%Global top 48% All 9 signals ▾Fundingtop 25% Growthtop 35% Moattop 42% Globaltop 48% Talenttop 50% Marketbottom 38% Techbottom 26% Newsbottom 20% Fin. healthbottom 10% Funding: Raised $681M across 8 rounds · 8 rounds over 17 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 27/100 | $681M | 12 mo ago | Series E | 54 | Oliver Buck Founder | TYPO3 CMSPHPBootstrap+8 | — | 1 award |
| 3 | ATAI 🦄 Biopharmaceutical company accelerating the development of mental health treatments | $387M | 63 mo ago | Public | 119 | Lars Christian Wilde Co-Founder | — | — | — |
| 4 | CatalYm Developer of drugs for the treatment of cancer 37Funding top 24%Moat top 28%Patents top 42%Innovation top 45% All 9 signals ▾Fundingtop 24% Moattop 28% Patentstop 42% Innovationtop 45% Growthtop 48% Globalbottom 39% Marketbottom 33% Techbottom 33% Newsbottom 17% Funding: Raised $261M across 3 rounds · 3 rounds over 10 yrs (0.3/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 23 patents rank vs industry peers · Fliar Intelligence Index 37/100 | $261M | 23 mo ago | Series D | 18 | — | WordPressApple iCloud MailMicrosoft 365+20 | 23 patents Therapeutic anti‑GDF15 antibodies for neoadjuvant and combination cancer treatment | — |
| 5 | Tubulis Technologies Developer of antibody-drug conjugates for the treatment of cancer 60News top 15%Funding top 18%Growth top 20%Patents top 27% All 10 signals ▾Newstop 15% Fundingtop 18% Growthtop 20% Patentstop 27% Moattop 28% Innovationtop 35% Talenttop 50% Marketbottom 42% Globalbottom 42% Techbottom 32% News: 13 BI events in 12 mo (of 21 tracked, 3 types) · +333% YoY Funding: Raised $214M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $214M | 8 mo ago | Acquired | 33 | Dominik Schumacher Co-Founder & CEO | WordPressMySQLPHP+14 | 70 patents Phosphorus‑based linkers for antibody‑drug conjugates targeting cancer antigens | — |
| 6 | Isarna Therapeutics Developer of TGF-B inhibitors based therapies for ophthalmic, fibrotic diseases and cancer | $158M | 145 mo ago | Series F | 3 | — | — | 64 patents Antisense oligonucleotide therapeutics targeting TGF‑β pathways for ocular disease treatment | — |
| 7 | iOmx Developer of checkpoint modulators for treating cancer | $120M | 56 mo ago | Series B | 33 33 → 53 (+61%) | — | WordPressMySQLPHP+10 | — | — |
| 8 | TRiCares Developer of a minimally invasive tricuspid valve replacement system. 27Funding top 21%Growth top 35%Moat top 36%Global bottom 47% All 9 signals ▾Fundingtop 21% Growthtop 35% Moattop 36% Globalbottom 47% Patentsbottom 42% Innovationbottom 36% Marketbottom 27% Techbottom 21% Newsbottom 18% Funding: Raised $103M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 27/100 | $103M | 4 mo ago | Series D | 12 | — | DrupalPleskPHP+3 | 3 patents Patents concentrated in health & consumer products | — |
| 9 | Medigene Developer of T cell immunotherapies for haematological malignancies 62Product top 14%Patents top 32%Funding top 34%Innovation top 37% All 12 signals ▾Producttop 14% Patentstop 32% Fundingtop 34% Innovationtop 37% Fin. healthtop 38% Growthtop 40% Moattop 41% Markettop 42% Partnerstop 45% Techbottom 44% Globalbottom 44% Newsbottom 26% Product: 5 distinct product lines · Company stage: Public Patents: 341 patents matched (strict assignee match) · 4 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $82M | 25 mo ago | Public | 114 | — | WordPressMySQLPHP+18 | 341 patents Patents concentrated in health & consumer products | — |
| 10 | SciRhom Developer of drugs for treating autoimmune disease 40Moat top 31%Patents top 32%Funding top 34%Talent top 38% All 8 signals ▾Moattop 31% Patentstop 32% Fundingtop 34% Talenttop 38% Innovationtop 41% Globalbottom 44% Marketbottom 30% Newsbottom 18% Moat: Editorial + unicorn rating 4/10 · IP moat: 29 patents Patents: 29 patents matched (strict assignee match) · 23 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $79M | 23 mo ago | Series A | 12 | Matthias Schneider Co-Founder & CSO | — | 29 patents Therapeutic antibodies and inhibitors targeting iRhom2 for disease treatment | — |
| 11 | Ingenium Pharamceutical Discovering drug targets through Deductive Genomics | $71M | 242 mo ago | Acquired | 41 | John Watkins President & CEO | — | — | — |
| 12 | SuppreMol Developer of therapeutics for the treatment of autoimmune diseases | $71M | 156 mo ago | Acquired | 50 | Jose Almeida CEO | — | 185 patents Therapeutic antibodies and soluble Fc receptor biologics for immune modulation | — |
| 13 | Morphochem German, late clinical stage biopharma developing oxazolidinone antibiotics for clostridium difficile… | $68M | 299 mo ago | Acquired | 1 | Alexis Rideau CEO | — | 28 patents Hybrid oxazolidinone‑quinolone antibiotics for parenteral bacterial infection treatment | — |
| 14 | veriNOS pharmaceuticals Developer of therapeutics for retina and brain diseases | $63M | 83 mo ago | Series G | 5 | Christian Wandersee CEO | — | — | — |
| 15 | Aspreva Pharmaceutics Develop medicines for rare autoimmune disorders | $57M | 267 mo ago | Acquired | 133 | — | — | — | — |
| 16 | Sapiens Neuro Developer of brain stimulation device to treat neurodegenerative disorders | $56M | 150 mo ago | Acquired | 59 | Sjaak Deckers ex-CEO | — | — | — |
| 17 | AdjuCor Developer of biventricular assistance device for chronic heart failure | $48M | 48 mo ago | Series B | 40 40 → 25 (-38%) | — | WordPressApple iCloud MailMicrosoft 365+20 | 49 patents Implantable cardiac ventricular assist devices with expandable pumps and structured surfaces | — |
| 18 | 4SC Mid-stage Biotech company discovering & developing small molecule cancer therapies based on epigenetic… | $42M | 123 mo ago | Public | 48 | — | WordPressMySQLPHP+10 | 621 patents Novel small‑molecule kinase and Kv1.3 ion‑channel inhibitors for cancer immunotherapy | — |
| 19 | HMNC Brain Health Developer of targeted therapies for depression and other neuropsychiatric disorders | $41M | 43 mo ago | Series B | 18 | — | Apple iCloud MailMicrosoft 365PHP+5 | — | — |
| 20 | CPTx Developer of programmable DNA therapeutics for a range of medical challenges 40Growth top 35%Funding top 37%Moat top 38%Talent top 38% All 9 signals ▾Growthtop 35% Fundingtop 37% Moattop 38% Talenttop 38% Techtop 46% Patentstop 50% Innovationbottom 43% Globalbottom 31% Marketbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $29.0M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $29M | 20 mo ago | Series B | — | Christian Sigl Founder & CTO | WordPressMySQLPHP+19 | 4 patents Peptide and nucleic‑acid therapeutic formulations and delivery methods | — |
| 21 | Ethris Developer of mRNA therapeutics for infectious diseases 55Patents top 25%Talent top 28%Moat top 29%Product top 30% All 11 signals ▾Patentstop 25% Talenttop 28% Moattop 29% Producttop 30% Innovationtop 35% Fundingtop 36% Growthtop 48% Techbottom 48% Marketbottom 44% Globalbottom 42% Newsbottom 27% Patents: 387 patents matched (strict assignee match) · 116 filings since 2022 vs 192 in 2017-21 Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 55/100 | $26M | 13 mo ago | Series B | 49 49 → 34 (-31%) | — | JimdoApple iCloud MailMicrosoft 365+10 | 387 patents mRNA therapeutics composition, manufacturing, and stabilization technologies | — |
| 22 | Innovative Molecules Developer of drugs to treat Herpes simplex-induced diseases | $24M | 60 mo ago | Series A | — | Gerald Kleymann Founder & CEO | MODXPHPUNIX+7 | 102 patents Antiviral small‑molecule thiazole/helicase‑primase inhibitors, including deuterated, enantiomeric, solid forms. | — |
| 23 | iThera Medical Solutions in photonic molecular imaging | $24M | 41 mo ago | Series D | 31 | — | — | 38 patents Patents concentrated in health & consumer products | — |
| 24 | ADVITOS Provider of multi-organ support systems | $24M | 59 mo ago | Series B | 88 88 → 89 (+1%) | Claus Jessen CEO | WordPressMySQLSalesforce+21 | 34 patents Extracorporeal CO₂ removal and lung support dialysis systems for medical respiratory therapy | 1 partnership |
| 25 | ISAR Bioscience Developer of regenerative medicine | $23M | 31 mo ago | Funding Raised | 19 | — | Master SliderWordPressMySQL+18 | 15 patents Patents concentrated in chemistry & materials | — |
| 26 | T-CURX Developer of immune-based cancer treatments with T-cells 27Funding top 40%Moat top 45%Patents bottom 49%Talent bottom 49% All 6 signals ▾Fundingtop 40% Moattop 45% Patentsbottom 49% Talentbottom 49% Globalbottom 40% Innovationbottom 36% Funding: Raised $21.4M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $21M | 6 mo ago | Series A | — | Christian Sollner Founder | — | 5 patents Non‑viral gene delivery vectors and engineered immune cells for therapeutic applications | — |
| 27 | Leon-nanodrugs Developer of technology for manufacturing lipid and polymeric nanoparticles for therapeutics 32Product top 21%Patents top 24%Innovation top 26%Moat top 32% All 10 signals ▾Producttop 21% Patentstop 24% Innovationtop 26% Moattop 32% Fundingtop 39% Talentbottom 49% Globalbottom 40% Techbottom 39% Newsbottom 21% Marketbottom 20% Product: 9 distinct product lines · Company stage: Series D Patents: 93 patents matched (strict assignee match) · 73 filings since 2022 vs 20 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $20M | 22 mo ago | Series D | 8 | Comelia Beier Co-Founder | WordPressMySQLPHP+18 | 93 patents Microfluidic aseptic mixing and disposable reactors for lipid nanoparticle drug production | — |
| 28 | PreOmics Provider of reagents and instruments for proteomics research | $19M | 53 mo ago | Series B | 22 | Nils Kulak Co-Founder & CEO | Webflow EcommerceWebflowSalesforce+17 | 59 patents Proteomics sample preparation and magnetic protein fractionation for mass spectrometry analysis | 1 job opening |
| 29 | NeuroCare Group Provider of noninvasive neurotechnology and personalized mental healthcare platform 48Tech top 29%Growth top 37%Moat top 39%Funding top 40% All 10 signals ▾Techtop 29% Growthtop 37% Moattop 39% Fundingtop 40% Patentstop 44% Talentbottom 49% Innovationbottom 48% Globalbottom 39% Marketbottom 34% Newsbottom 18% Tech: 48 technologies across 5/8 capability areas · Cloud: Cloudflare Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $17M | 16 mo ago | Series B | 14 | Thomas Mechtersheimer Founder & CEO | Cart FunctionalityWooCommerceWordPress+28 | 9 patents Adaptive transcranial stimulation systems integrating real-time physiological feedback for personalized therapy | 1 partnership |
| 30 | mbiomics Provider of a genomic-based platform for microbiome-based therapeutics development 21Funding top 39%Patents top 39%Moat top 42%Innovation top 50% All 6 signals ▾Fundingtop 39% Patentstop 39% Moattop 42% Innovationtop 50% Globalbottom 36% Marketbottom 26% Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 21/100 | $14M | 1 mo ago | Series A | 7 | — | — | 13 patents RNA purification methods and microbiome analysis/composition technologies for diagnostic applications | — |
| 31 | PreciPoint Developer of digital microscopes and micro-positioning systems | $10M | 46 mo ago | Series A | 37 37 → 44 (+19%) | Dominik Gerber Co-CEO | PHPMicrosoft 365Cloudflare Browser Insights+2 | 43 patents High‑resolution digital microscopy imaging, whole‑slide scanning, image archiving, and distributed analysis | 2 launchs · 1 partnership |
| 32 | XO Life Provider of digital platform for pharmaceutical and medical device treatment support 48Patents top 19%Moat top 25%Talent top 28%Growth top 35% All 11 signals ▾Patentstop 19% Moattop 25% Talenttop 28% Growthtop 35% Fundingtop 40% Innovationtop 44% Productbottom 45% Techbottom 44% Globalbottom 44% Marketbottom 28% Newsbottom 22% Patents: 82 patents matched (strict assignee match) · 29 filings since 2022 vs 28 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 82 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 21 mo ago | Series A | 25 | Philipp Naegelein Co-Founder | WebflowAmazon Web ServicesMicrosoft Clarity+9 | 82 patents Molecular biology automation: nucleic acid synthesis, fluorescence imaging, and spectral/auto‑focus instrumentation. | — |
| 33 | Brainlab Software and integrated solutions for surgical and radiotherapy applications 82Fin. health top 18%Patents top 19%Innovation top 27%Tech top 28% All 12 signals ▾Fin. healthtop 18% Patentstop 19% Innovationtop 27% Techtop 28% Markettop 29% Moattop 29% Partnerstop 41% Fundingtop 43% Globaltop 45% Producttop 46% Growthtop 50% Newsbottom 23% Fin. health: Revenue ~$459M · Revenue +18% YoY Patents: 2,839 patents matched (strict assignee match) · 676 filings since 2022 vs 939 in 2017-21 rank vs industry peers · Fliar Intelligence Index 82/100 | $7M | 18 mo ago | Series B | 348 | — | SentryApple iCloud MailNode.js+18 | 2,839 patents Image-guided neurosurgery, radiation therapy planning, and AI-driven medical imaging analysis | 3 launchs |
| 34 | CertHub Provider of quality management system and documentation solutions for medical device manufacturers 32Talent top 38%Funding top 40%Market bottom 37%Global bottom 36% All 4 signals ▾Talenttop 38% Fundingtop 40% Marketbottom 37% Globalbottom 36% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $7.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $7M | 5 mo ago | Seed | — | Nicolas Gehring Co-Founder & CTO | — | — | — |
| 35 | Dynamic Biosensors Provides solutions for label-free molecular interaction and biophysical analysis | $6M | 45 mo ago | Acquired | 51 51 → 62 (+22%) | — | WordPressMySQLPHP+24 | 33 patents Microfluidic cell immobilization and bubble control for protein‑small molecule biosensing | 1 launch |
| 36 | Reactive Robotics Developer of robotic hospital equipment for early mobilization | $6M | 21 mo ago | Series A | 18 | — | — | 107 patents Patient rehabilitation hardware: modular coupling and support devices for limb and body positioning. | — |
| 37 | Ovo Labs Developer of therapeutics designed to improve the quality of human eggs 37Talent top 28%Growth top 45%Funding top 48%Global bottom 45% All 6 signals ▾Talenttop 28% Growthtop 45% Fundingtop 48% Globalbottom 45% Techbottom 42% Marketbottom 31% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $5M | 13 mo ago | Seed | — | Oleksandr Yagensky Co-Founder & Co-CEO | Cart FunctionalitySquarespace CommerceSquarespace+14 | — | 2 awards |
| 38 | Eisbach Developer of targeted therapy for cancer treatment | $5M | 26 mo ago | Series A | 13 | Adrian Schomburg Co-Founder & CEO | WordPressMySQLPHP+20 | — | — |
| 39 | Sedivention Developer of a minimally invasive cryo-ablation therapy for obesity. 22Talent top 38%Funding top 43%Moat top 45%Market bottom 37% All 7 signals ▾Talenttop 38% Fundingtop 43% Moattop 45% Marketbottom 37% Patentsbottom 33% Globalbottom 33% Innovationbottom 29% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $4.2M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $4M | 1 mo ago | Seed | — | André Burch Co-Founder | — | 2 patents Cryogenic ablation tools for minimally invasive tumor destruction | — |
| 40 | Umlaut.bio Developer of small-molecule therapeutics for cancer 32Growth top 35%Funding top 44%Talent bottom 49%Tech bottom 48% All 6 signals ▾Growthtop 35% Fundingtop 44% Talentbottom 49% Techbottom 48% Globalbottom 37% Marketbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $3.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $4M | 3 mo ago | Seed | — | Karsten Fischer CEO | WordPressPleskMySQL+29 | — | — |
| 41 | IRUBIS Developer of analytical technology for real-time bioprocess monitoring and analysis | $3M | 21 mo ago | Seed | 15 15 → 20 (+33%) | Lorenz Mirle Co-Founder | — | 8 patents Optical spectroscopy flow cells and disposable bioreactors for bioprocess monitoring | — |
| 42 | Cellbyte AI-driven analytics platform that enables pricing and market access professionals in the pharmaceutical… 40Talent top 28%AI top 35%Funding top 39%Global bottom 48% All 6 signals ▾Talenttop 28% AItop 35% Fundingtop 39% Globalbottom 48% Techbottom 43% Marketbottom 25% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-driven, natural language processing rank vs industry peers · Fliar Intelligence Index 40/100 | $3M | 6 mo ago | Seed | — | Felix Steinbrenner Co-Founder | Framer SitesApple iCloud MailGoogle Workspace+9 | — | — |
| 43 | AATec Medical Developer of therapeutics to treat immunological diseases | $3M | 14 mo ago | Seed | 6 | Michael Strassmair Managing Director | WordPress Block EditorElementorWordPress+23 | 22 patents Recombinant alpha‑1 antitrypsin biologics for treating lung inflammation and viral infections | — |
| 44 | UniteLabs Provider of an automation operating system for laboratory workflows 37Talent top 38%AI top 45%Funding bottom 43%Market bottom 37% All 5 signals ▾Talenttop 38% AItop 45% Fundingbottom 43% Marketbottom 37% Globalbottom 37% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated AI: Product described with: ai-driven rank vs industry peers · Fliar Intelligence Index 37/100 | $3M | 14 mo ago | Seed | — | Robert Zechlin Co-Founder & Co-CEO | — | — | — |
| 45 | Evanium Developer of selective alcohol antagonist 10Talent top 28%Funding bottom 46%Global bottom 29%Tech bottom 24% All 5 signals ▾Talenttop 28% Fundingbottom 46% Globalbottom 29% Techbottom 24% Marketbottom 20% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $2.6M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 10/100 | $3M | 2 mo ago | Seed | 5 | David Ofner Co-Founder | WordPressMySQLPHP+17 | — | 1 launch · 1 award |
| 46 | Lilio Provider of baby monitoring devices for parents to understand the childs needs | $2M | 30 mo ago | Seed | — | Nadine Wunderlich Co-Founder & CEO | — | — | — |
| 47 | brainjo AI based plafrom providing cognitive training 21AI top 35%Funding top 44%Talent bottom 49%Product bottom 45% All 7 signals ▾AItop 35% Fundingtop 44% Talentbottom 49% Productbottom 45% Globalbottom 32% Techbottom 31% Marketbottom 22% AI: Product described with: ai based, ai-based Funding: Raised $2.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $2M | 1 mo ago | Seed | — | Christian Gnerlich Founder | MyWebsiteDudaMyWebsite Creator+10 | — | — |
| 48 | Mallia Therapeutics Developer of therapeutics for hair loss | $2M | 20 mo ago | Seed | — | Alexander Stein Co-Founder & Managing Director | — | — | — |
| 49 | Differential Bio Provider of bioprocess optimization through robotic lab automation and AI insights | $2M | 14 mo ago | Seed | — | Martin Patz Co-Founder & CTO | WebflowjsDelivrGoogle Hosted Libraries+9 | — | — |
| 50 | smartbax Developer of multi-targeted antibacterial compounds 14Talent top 38%News top 43%Moat top 48%Funding top 49% All 6 signals ▾Talenttop 38% Newstop 43% Moattop 48% Fundingtop 49% Globalbottom 32% Marketbottom 22% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated News: 2 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding rank vs industry peers · Fliar Intelligence Index 14/100 | $2M | 7 mo ago | Seed | 3 | Stephan Sieber Co-Founder | — | — | — |
Top 12 Life Sciences companies in Bavaria
#1
Series D · Aschheim, Bavaria · founded 2013 · 12 employees$102.8Mraised▾
Series D · Aschheim, Bavaria · founded 2013 · 12 employees
{}
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 21%Growth
top 35%Moat
top 36%Global
bottom 47%Patents
bottom 42%Innovation
bottom 36%Funding: Raised $103M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) · Last round Conventional Debt (Jan 2026)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents · Soonicorn
Funding rounds
- Jan 2026Conventional Debt$23.3M
- Jul 2024Series D$50M
- Sep 2022Series C$52.8M
- Nov 2021Grant (prize money)$56.4K
Investors
EIC Fund, Europa, 415 CAPITAL, Andera Partners, BioMedPartners, Credit Mutuel Equity
Tech stack
DrupalJqueryNginxPhpPleskPwa
#2
Series E · Munich, Bavaria · founded 2004 · 54 employees$681Mraised▾
Series E · Munich, Bavaria · founded 2004 · 54 employees
Developer of radiopharmaceuticals and radioisotopes for cancer treatment. The company's lead product is radionuclide therapy candidate LuCaFab (ITM-31) for the treatment of malignant brain tumors. The company offers medical isotopes like EndolucinBeta and TOCscan. It also offers radiolabelling and quality control equipment like iQS - Theranostics Synthesizer, iQS Ga-68, Fluidic Labeling, Module Reagent Set Manual, and 177Lu Labeling.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 25%Growth
top 35%Moat
top 42%Global
top 48%Talent
top 50%Market
bottom 38%Funding: Raised $681M across 8 rounds · 8 rounds over 17 yrs (0.5/yr) · Last round Conventional Debt (May 2025)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 5/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 7.1% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- May 2025Conventional Debt$262.5M
- Jun 2024Series E$204.4M
- Jun 2023Series E$273M
- Mar 2022Series D$36.4M
Founders & team
Investors
Temasek, BlackRock, Qatar Investment Authority, Carbyne Equity Partners, ATHOS, European Investment Bank
Tech stack
Apache Http ServerBootstrapIonosJqueryLightboxMatomo Analytics
#3
Acquired · Munich, Bavaria · founded 2015 · 33 employees$214.1Mraised▾
Acquired · Munich, Bavaria · founded 2015 · 33 employees
Developer of antibody-drug conjugates for the treatment of cancer. The company has proprietary technology platforms which include the Tub-tag conjugation platform, P5 conjugation platform, and Topoisomerase-I inhibitor platform to develop antibody-drug conjugates for solid and hematological tumors. It offers TUB-040 for ovarian and non-small cell lung cancer. TUB-030, TUB-050, and TUB-060 for solid tumors.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
News
top 15%Funding
top 18%Growth
top 20%Patents
top 27%Moat
top 28%Innovation
top 35%News: 13 BI events in 12 mo (of 21 tracked, 3 types) · +333% YoY · 12 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding: Raised $214M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Series C (Oct 2025)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 18k LinkedIn followers — 5.3% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series C$401M
- Mar 2024Series B$138.8M
- Aug 2022Grant (prize money)—
- May 2022Series B$63.1M
Founders & team
Investors
Nextech Invest, Deep Track Capital, Frazier Life Sciences, Andera Partners, BioMedPartners, Bayern Kapital
Tech stack
All-InklApache Http ServerBorlabs CookieCore-JsElementorJquery
#4
Series A · Munich, Bavaria · founded 2020 · 7 employees$14Mraised▾
Series A · Munich, Bavaria · founded 2020 · 7 employees
Provider of a genomic-based platform for microbiome-based therapeutics development. It offers platforms that combine DNA and RNA analysis for single or molecule detection which includes GOLD for microbiome analysis, monitors to track microbiome modulation, and STRATOS for microbiome profiling.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 39%Patents
top 39%Moat
top 42%Innovation
top 50%Global
bottom 36%Market
bottom 26%Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series A (Apr 2026)
Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 4/10 · IP moat: 13 patents · 9 curated direct competitors tracked
Audience (LinkedIn): 10k LinkedIn followers — 3.1% of this cohort's audience
Funding rounds
- Apr 2026Series A$14.1M
- Mar 2023Series A$14M
Investors
Bayern Kapital, HTGF, MIG Fonds
#5
Series A · Wurzburg, Bavaria · founded 2016$21.4Mraised▾
Series A · Wurzburg, Bavaria · founded 2016
T-CURX is developing immune-based cancer treatments with T-cells. They are developing new generation UltraModularCAR T cells (transformative, chemotherapy-free treatment) for treating leukemia, lymphoma, breast cancer, and lung cancer. It's in phase I/II a clinical trial for safety and efficacy evaluation.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 40%Moat
top 45%Patents
bottom 49%Talent
bottom 49%Global
bottom 40%Innovation
bottom 36%Funding: Raised $21.4M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) · Last round Series A (Dec 2025)
Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents
Patents: 5 patents matched (strict assignee match) · 3 filings since 2022 vs 2 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Britiel Cancer Institute (BCI)) announced in 12 mo
Funding rounds
- Dec 2025Series A$20.8M
- Jan 2018Grant (prize money)$605.1K
Founders & team
Investors
Europa, BioMedPartners, Bayern Kapital, Hlc Fund, i and iBio Fund
#6
Seed · Munich, Bavaria · founded 2021$4.2Mraised▾
Seed · Munich, Bavaria · founded 2021
{}
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Talent
top 38%Funding
top 43%Moat
top 45%Market
bottom 37%Patents
bottom 33%Global
bottom 33%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $4.2M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Seed (May 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 2 patents
Audience (LinkedIn): 449 LinkedIn followers
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- May 2026Seed$3.4M
- Nov 2024Seed$843.1K
Founders & team
Investors
HTGF, Bmp Ventures, IBG Beteiligungsgesellschaft Sachsen-Anhalt, Superangles, Cambridge Venture Partners, BioVaria
#7
Seed · Regensburg, Bavaria · founded 2017 · 5 employees$2.6Mraised▾
Seed · Regensburg, Bavaria · founded 2017 · 5 employees
Evanium is developing a selective alcohol antagonist. The company is developing the therapeutics which is a negative modulator of the GABAA receptor and can antagonize the effect of alcohol on the central nervous system antagonizes the effect of alcohol on the central nervous system.
Fliar Intelligence Index™ 10how this company ranks against its industry peers
Talent
top 28%Funding
bottom 46%Global
bottom 29%Tech
bottom 24%Market
bottom 20%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $2.6M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Apr 2026)
Global: Single-market focus (Germany)
Audience (LinkedIn): 983 LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 awards announced in 12 mo
Funding rounds
- Apr 2026Seed$2.6M
Founders & team
Investors
FoodLabs, Feast Ventures
Tech stack
Animate.CssApache Http ServerCore-JsElementorGoogle MapsHello Elementor
#8
Seed · Regensburg, Bavaria · founded 2019$2.4Mraised▾
Seed · Regensburg, Bavaria · founded 2019
Brainjo is an AI-based platform that provides cognitive training. The company tests the physical and cognitive performance of the individual and set personal goals. It creates a personal training plan for physical-mental training. It provides training like reaction training, neurofeedback, and brain jogging.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
AI
top 35%Funding
top 44%Talent
bottom 49%Product
bottom 45%Global
bottom 32%Tech
bottom 31%AI: Product described with: ai based, ai-based
Funding: Raised $2.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Apr 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Apr 2026Seed$2.4M
Founders & team
Investors
HTGF, better ventures, MEDICE Arzneimittel Pütter
Tech stack
DudaHstsJqueryJquery MigrateLodashMicrosoft 365
#9
Seed · Augsburg, Bavaria · founded 2024$7.3Mraised▾
Seed · Augsburg, Bavaria · founded 2024
Provider of quality management system and documentation solutions for medical device manufacturers. It provide scripts, systemd units, and docker images for centralized TLS certificate management with git as a backend.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Talent
top 38%Funding
top 40%Market
bottom 37%Global
bottom 36%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $7.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Jan 2026)
Funding rounds
- Jan 2026Seed$7.3M
Founders & team
Investors
Cusp Capital, D11Z.Ventures, Calm/Storm, UnternehmerTUM
#10
Seed · Aschaffenburg, Bavaria · founded 2022$3.5Mraised▾
Seed · Aschaffenburg, Bavaria · founded 2022
Developer of small-molecukle therapeutics for cancer. It offers chemically modified RNA nucleotides that prevent the growth of cancer cells and helps treat multiple cancer.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Growth
top 35%Funding
top 44%Talent
bottom 49%Tech
bottom 48%Global
bottom 37%Market
bottom 25%Growth: Fresh capital in last 24 mo
Funding: Raised $3.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Feb 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 717 LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. BaseLaunch and Prof. Distler and Prof. Suzuki) announced in 12 mo
Funding rounds
- Feb 2026Seed$3.5M
Founders & team
Investors
HTGF, LBBW Venture Capital, ONO PHARMACEUTICAL, Mission BioCapital, AbbVie
Tech stack
All In One SeoAnimate.CssApache Http ServerBootstrapCloudflareCloudflare Bot Management
#11
Series D · Munich, Bavaria · founded 2016 · 18 employees$260.6Mraised▾
Series D · Munich, Bavaria · founded 2016 · 18 employees
Developer of drugs for the treatment of cancer. The lead candidate includes CTL-002 which works by neutralizing tumour-produced proteins called GDF-15. It is used to treat cancer and autoimmune disease.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 24%Moat
top 28%Patents
top 42%Innovation
top 45%Growth
top 48%Global
bottom 39%Funding: Raised $261M across 3 rounds · 3 rounds over 10 yrs (0.3/yr) · Last round Series D (Jul 2024)
Moat: Editorial + unicorn rating 8/10 · IP moat: 23 patents · Soonicorn
Patents: 23 patents matched (strict assignee match) · 23 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Jul 2024Series D$150M
- Nov 2022Series C$51.3M
- Nov 2020Series B$59.3M
- 2016Seed—
Investors
BioGeneration Ventures, Canaan, Bioqube Ventures, Forbion, Omega Funds, Gilde Healthcare
Tech stack
Animate.CssAosApple Icloud MailContact Form 7Core-JsFont Awesome
#12
Series B · Planegg, Bavaria · founded 2009 · 49 employees$26.3Mraised▾
Series B · Planegg, Bavaria · founded 2009 · 49 employees
Developer of mRNA therapeutics for infectious diseases. It has two proprietary platforms for SNIM RNA technology (Stabilized Non-Immunogenic mRNA) for transcript therapy and SNIM RNA delivery system. The platforms enable the designing of mRNA for the protein of interest and chemical modification of the nucleotide backbone to bypass the innate immune response and targeted delivery. The pipeline includes therapeutics for COVID-19, respiratory diseases, and Primary ciliary dyskinesia (PCD).
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Patents
top 25%Talent
top 28%Moat
top 29%Product
top 30%Innovation
top 35%Funding
top 36%Patents: 387 patents matched (strict assignee match) · 116 filings since 2022 vs 192 in 2017-21 · Latest publication 2026
Talent: Analyst team rating 4/5
Moat: Editorial + unicorn rating 7/10 · IP moat: 387 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. German Center for Infection Research (DZIF)) announced in 12 mo
Funding rounds
- May 2025Grant (prize money)$11.3M
- Jun 2024Series B$5M
- Feb 2022Series B$26.3M
- Jan 2020Grant (prize money)$550.3K
Investors
Europa, Laureus Capital, EU4health, Gates, Orbimed
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCore-JsGodaddyHsts
Funding & investor landscape
$4.1Btotal disclosed funding
108companies funded
254disclosed rounds
4rounds last 90 days
Most active investors
Notable founders
Oliver Buck
Founder · ITM
Steffen Schuster
CEO · ITM
Dominik Schumacher
Co-Founder & CEO · Tubulis Technologies
Jonas Helma-Smets
Co-Founder & CSO · Tubulis Technologies
Christian Sollner
Founder · T-CURX
André Burch
Co-Founder · Sedivention
Ute Nollert
Founder & CEO · Sedivention
David Ofner
Co-Founder · Evanium
Carlo Werkmann
Co-Founder · Evanium
Christian Gnerlich
Founder · brainjo
Nicolas Gehring
Co-Founder & CTO · CertHub
Leon Kobinger
Co-Founder & CEO · CertHub
Prism market signals · Germany · country-scoped Prism corpus, 141,341 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Germany
How research on Biotechnology is moving in Germany
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,297 Germany-affiliated papers.
research sentiment over time
200820152026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 38% → 41% across 2008–2026.
top research entities
- Heidelberg University85
- German Cancer Research Center49
- Ludwig-Maximilians-Universität München48
- Technical University of Munich43
- Karlsruhe Institute of Technology33
leading researchers
Lennart Hilbert · Henry Reyer · Michael Oster · Nares Trakooljul · Badhe, Pravin · Avon Augustin Nalpadan · Siriluck Ponsuksili · Ralf Nauen
▲
Breakthroughs421 · 32%
▼ 35%→31% share
▼0.9× share momentum0 median citations78% since 2021mostly empirical
Messenger RNA research surged 1→14 papers, with Genome and RNA polymerase II newly emerging, signaling intensifying transcriptional mechanism focus.
rising sub-themes (early→recent)
- Gene3→29
- Mutant3→19
- Transcription (linguistics)3→16
- Messenger RNA1→14
- Immune system1→12
Newly emergingGenome 0→15 · Mutation 0→13 · RNA polymerase II 0→9
Landmark The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets · 4,863 cites
◆
Advancements429 · 33%
33%→33% share
▲1.0× share momentum0 median citations82% since 2021mostly empirical
Downregulation/upregulation and Selection newly emerged while Agriculture tripled (2→12), reflecting rising gene-regulation and crop-biotech output.
rising sub-themes (early→recent)
- Gene3→20
- Agriculture2→12
- Extracellular1→11
- Immune system1→11
- Transcriptome1→9
Newly emergingDownregulation and upregulation 0→12 · Selection (genetic algorithm) 0→11 · Antibody 0→10
Landmark Regulation of the Voltage Gated K<sup>+</sup> Channel K<sub>v1.3</sub> by Recombinant Human Klot · 5,606 cites
▼
Concerns184 · 14%
▼ 17%→14% share
▼0.8× share momentum0 median citations79% since 2021mostly empirical
Antibiotic resistance and Agriculture concerns both rose sharply (2→9, 4→9), with Sustainability newly flagged across German biotech research.
rising sub-themes (early→recent)
- Antibiotic resistance2→9
- Gene1→7
- Agriculture4→9
- Antimicrobial1→4
- Microbiome1→4
Newly emergingContext (archaeology) 0→11 · Sustainability 0→9 · Production (economics) 0→7
Landmark Prebiotic effects: metabolic and health benefits · 2,037 cites
RESEARCH HOTSPOTS · Germany
Where biotechnology is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Munich119 · +0.49
Berlin91 · +0.38
Heidelberg90 · +0.52
Jülich/Bonn72 · +0.41
Karlsruhe34 · +0.30
Aachen23 · +0.51
Dresden22 · +0.54
Stuttgart7 · +0.56
PATENT SIGNAL · Germany
Who's filing biotechnology patents in Germany
Germany biotechnology patent filing is cooling — 53,233 filings from 8,000 assignees (2016–2025), led by Immatics Biotechnologies, BASF Plant Science, BASF SE; annual filings 4819→4267.
53,233 filings8,000 assigneespeak 6040/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Immatics Biotechnologies4875
- BASF Plant Science3993
- BASF SE3545
- Boehringer Ingelheim INT3440
- Merck Patent3137
- MAX Planck Gesellschaft1805
- Evonik Degussa1683
- Amgen RES Munich1665
Common questions
How many Life Sciences companies are there in Bavaria, Germany?
Radar tracks 291 indexable Life Sciences companies headquartered in Bavaria, Germany that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Bavaria, Germany?
The Life Sciences companies in Bavaria, Germany on this list have raised a combined $4.1B in disclosed equity funding across 108 funded companies.
Which is the highest-funded Life Sciences company in Bavaria, Germany?
MorphoSys is the highest-funded Life Sciences company in Bavaria, Germany, with $770.1M in disclosed equity funding.
How many Life Sciences companies in Bavaria, Germany are funded?
108 of the 291 Life Sciences companies in Bavaria, Germany on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Bavaria, Germany?
1 Life Sciences company in Bavaria, Germany on this list is valued at $1B or more.
Who are the top investors in Bavaria, Germany Life Sciences companies?
The most active investors in Bavaria, Germany Life Sciences companies on this list include Europa, Bayern Kapital, HTGF, EIC Fund, Kfw.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.